Join Growin Stock Community!

Calidi biotherapeutics, inc.CLDI.US Overview

US StockHealthcare
(No presentation for CLDI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CLDI AI Insights

CLDI Overall Performance

CLDI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CLDI Recent Performance

-6.34%

Calidi biotherapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CLDI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CLDI Key Information

CLDI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CLDI Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

Price of CLDI

CLDI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CLDI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.78
PE Ratio (TTM)
2.21
Forward PE
-
PS Ratio (TTM)
50.83
PB Ratio
0.82
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.78
PE Ratio (TTM)
2.21
Forward PE
-
PS Ratio (TTM)
50.83
PB Ratio
0.82
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CLDI's latest earnings report released?

    The most recent financial report for Calidi biotherapeutics, inc. (CLDI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CLDI's short-term business performance and financial health. For the latest updates on CLDI's earnings releases, visit this page regularly.

  • How much debt does CLDI have?

    As of the end of the reporting period, Calidi biotherapeutics, inc. (CLDI) had total debt of 3.31M, with a debt ratio of 0.24. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CLDI have?

    At the end of the period, Calidi biotherapeutics, inc. (CLDI) held Total Cash and Cash Equivalents of 10.38M, accounting for 0.74 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CLDI's EPS continuing to grow?

    According to the past four quarterly reports, Calidi biotherapeutics, inc. (CLDI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CLDI?

    Calidi biotherapeutics, inc. (CLDI)'s Free Cash Flow (FCF) for the period is -4.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.87% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CLDI?

    The latest valuation data shows Calidi biotherapeutics, inc. (CLDI) has a Price-To-Earnings (PE) ratio of -0.43 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.